Conclusion
TMP-SMX prophylaxis was associated with subsequent reduced serious and overall infections in patients with GPA treated with rituximab. Further study is needed to determine how to balance potential benefits and harms from prophylaxis in individual patients and determine optimal prophylaxis duration.
Disclosures
A. Mendel: None; H. Behlouli: None; E. Vinet: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, CorEvitas, 2, 5, Eli Lilly and Company, 2, 5, Janssen, 2, 5, Myriad, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5; S. Bernatsky: None.
Mendel A, Behlouli H, Vinet E, Curtis J, Bernatsky S. Effect of trimethoprim sulfamethoxazole prophylaxis on infections during treatment of granulomatosis with polyangiitis with rituximab: A population-based study [abstract]. Arthritis Rheumatol. 2023;75(suppl 9).